Abstract
High-throughput sequencing technologies have enabled comprehensive characterization of somatic variants of diagnostic, prognostic and/or therapeutic actionability in hematological malignancies. However, substantial discrepancy in interpreting these variants exists among testing labs, which creates challenges in patient management. To address this issue, the ClinGen Somatic Cancer Clinical Domain working group formed the Hematological Cancer Taskforce (HCT) [January 2020] composed of 45 multi-disciplinary experts including oncologists, molecular pathologists, lab directors, genomic scientists and biocurators with expertise in hematological malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
